$1.58
4.64% day before yesterday
Nasdaq, Nov 14, 10:15 pm CET

MaxCyte Inc Stock price

$1.58
-0.07 4.24% 1M
-0.62 28.18% 6M
-2.58 62.02% YTD
-1.86 54.07% 1Y
-5.35 77.20% 3Y
-0.05 3.07% 5Y
-0.01 0.83% 10Y
-0.01 0.83% 20Y
Nasdaq, Closing price Fri, Nov 14 2025
+0.07 4.64%

Key metrics

Basic
Market capitalization
$168.4m
Enterprise Value
$41.9m
Net debt
positive
Cash
$126.6m
Shares outstanding
106.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.7 | 4.5
EV/Sales
1.2 | 1.1
EV/FCF
negative
P/B
0.9
Financial Health
Equity Ratio
86.1%
Return on Equity
-19.9%
ROCE
-25.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$35.8m | $37.1m
EBITDA
$-49.3m | $-37.8m
EBIT
$-53.5m | $-55.1m
Net Income
$-44.8m | $-46.4m
Free Cash Flow
$-38.3m
Growth (TTM | estimate)
Revenue
-21.3% | -3.9%
EBITDA
-17.1% | 19.6%
EBIT
-15.5% | -7.6%
Net Income
-26.4% | -13.0%
Free Cash Flow
-50.8%
Margin (TTM | estimate)
Gross
79.8%
EBITDA
-137.9% | -101.9%
EBIT
-149.6%
Net
-125.2% | -124.9%
Free Cash Flow
-107.0%
More
EPS
$-0.4
FCF per Share
$-0.4
Short interest
2.9%
Employees
114
Rev per Employee
$340.0k
Show more

Is MaxCyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

MaxCyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a MaxCyte Inc forecast:

10x Buy
77%
3x Hold
23%

Analyst Opinions

13 Analysts have issued a MaxCyte Inc forecast:

Buy
77%
Hold
23%

Financial data from MaxCyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
36 36
21% 21%
100%
- Direct Costs 7.23 7.23
38% 38%
20%
29 29
29% 29%
80%
- Selling and Administrative Expenses 55 55
5% 5%
153%
- Research and Development Expense 22 22
9% 9%
62%
-49 -49
17% 17%
-138%
- Depreciation and Amortization 4.18 4.18
0% 0%
12%
EBIT (Operating Income) EBIT -53 -53
16% 16%
-150%
Net Profit -45 -45
26% 26%
-125%

In millions USD.

Don't miss a Thing! We will send you all news about MaxCyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MaxCyte Inc Stock News

Neutral
Seeking Alpha
3 days ago
MaxCyte, Inc. ( MXCT ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Maher Masoud - President, CEO & Executive Director Douglas Swirsky - Chief Financial Officer Conference Call Participants Matthew Larew - William Blair & Company L.L.C., Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Vidyun Bais - BTIG, LLC, Research Division Han...
Neutral
GlobeNewsWire
3 days ago
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that Chief Financial Officer Douglas Swirsky has informed the Company of his decision to transition from his role in...
Neutral
GlobeNewsWire
3 days ago
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its third quarter ended September 30, 2025 financial results and reiterated its 2025 guidance.
More MaxCyte Inc News

Company Profile

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Maher Masoud
Employees 114
Founded 1998
Website www.maxcyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today